Authors' reply to the comment “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa”

Mondana H. Ghias; Andrew D. Johnston; Allison J. Kutner; Robert G. Micheletti; H. Dean Hosgood; Steven R. Cohen

doi:10.1016/j.jaad.2020.11.041

Authors' reply to the comment “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa”

Mondana H. Ghias, Andrew D. Johnston, Allison J. Kutner, Robert G. Micheletti, H. Dean Hosgood, Steven R. Cohen

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e203-e204
Journal	Journal of the American Academy of Dermatology
Volume	84
Issue number	4
DOIs	https://doi.org/10.1016/j.jaad.2020.11.041
State	Published - Apr 2021

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2020.11.041

Cite this

@article{9db4bdee5e0c4af597ed91ba29970762,

title = "Authors' reply to the comment “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa”",

author = "Ghias, {Mondana H.} and Johnston, {Andrew D.} and Kutner, {Allison J.} and Micheletti, {Robert G.} and Hosgood, {H. Dean} and Cohen, {Steven R.}",

note = "Funding Information: Funding sources: Dr Johnston was supported by Einstein's Medical Scientist Training Program, National Institutes of Health , National Institute of General Medical Sciences grant T32 GM007288 . ",

year = "2021",

month = apr,

doi = "10.1016/j.jaad.2020.11.041",

language = "English (US)",

volume = "84",

pages = "e203--e204",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - Authors' reply to the comment “High-dose, high-frequency infliximab

T2 - A novel treatment paradigm for hidradenitis suppurativa”

AU - Ghias, Mondana H.

AU - Johnston, Andrew D.

AU - Kutner, Allison J.

AU - Micheletti, Robert G.

AU - Hosgood, H. Dean

AU - Cohen, Steven R.

N1 - Funding Information: Funding sources: Dr Johnston was supported by Einstein's Medical Scientist Training Program, National Institutes of Health , National Institute of General Medical Sciences grant T32 GM007288 .

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85101689945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101689945&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.11.041

DO - 10.1016/j.jaad.2020.11.041

M3 - Letter

C2 - 33253838

AN - SCOPUS:85101689945

SN - 0190-9622

VL - 84

SP - e203-e204

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 4

ER -

Authors' reply to the comment “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa”

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this